NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-AA-22-014 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-22-504 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Heart, Lung and Blood Institute (NHLBI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), invites applications for a limited competition for the two Clinical Coordinating Centers (CCCs) already involved in The Chronic Kidney Disease in Children Study (CKiD) Consortium. The clinical centers will continue to evaluate enrolled participants, recruit new participants, and continue to work together cooperatively with the existing Data Coordinating Center (DCC) and Central Biochemistry Laboratory (CBL) of the study as a consortium.
Funding Opportunity RFA-DK-22-010 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Heart, Lung and Blood Institute (NHLBI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), invites applications for the Central Biochemistry Laboratory (CBL) for the Chronic Kidney Disease in Children Study (CKiD) Consortium. The CBL will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and the Data Coordinating Center (DCC) of the study as a consortium.
Funding Opportunity RFA-DK-22-505 from the NIH Guide for Grants and Contracts. The NIDDK, in collaboration with the NHLBI and NICHD, invites an application for a limited competition for the Data Coordinating Center (DCC) already involved in The Chronic Kidney Disease in Children Study (CKiD) Consortium. The DCC will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and Central Biochemistry Laboratory (CBL) of the study as a consortium.
Funding Opportunity PAR-22-210 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings. The overall goal is to inform and support efforts to prevent or reduce exposure to harmful environmental exposures and improve the health of a community.
Funding Opportunity RFA-OD-22-015 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this ORWH R25 program is to support educational activities that complement and/or enhance the training of a diverse workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Curriculum or Methods Development. Specifically, this FOA will support the development of short courses, training modules, curricula, and other educational activities to enhance knowledge of sex and gender influences on health and disease among scientists, clinicians, and health professionals, and other stakeholders to accelerate the translation of that knowledge into practice.
Notice NOT-PM-22-003 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-177 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-176 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-21-031 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. This might also require the development of appropriate community standards, and reference materials when not already available.
Funding Opportunity PAS-22-206 from the NIH Guide for Grants and Contracts. This HEAL FOA provides an opportunity for early career researchers or early career clinicians with foundational backgrounds in addiction to develop expertise in implementation science. Successful applicants would propose training in implementation science methods, and a research project that would apply these to at least one of the four priority domains of the HHS Overdose Prevention Strategy: primary prevention (including appropriate opioid prescribing), OUD treatment, harm reduction, and/or recovery support services. The overarching goal is to build a cadre of implementation researchers who can contribute to addressing the current overdose crisis, develop research careers that will impact the quality of addiction clinical practice generally, and become the next generation of implementation experts and mentors.
Funding Opportunity PAS-22-207 from the NIH Guide for Grants and Contracts. This HEAL FOA provides an opportunity for early career researchers or early career clinicians with foundational backgrounds in addiction to develop expertise in implementation science. Successful applicants would propose training in implementation science methods, and a research project that would apply these to at least one of the four priority domains of the HHS Overdose Prevention Strategy: primary prevention (including appropriate opioid prescribing), OUD treatment, harm reduction, and/or recovery support services. The overarching goal is to build a cadre of implementation researchers who can contribute to addressing the current overdose crisis, develop research careers that will impact the quality of addiction clinical practice generally, and become the next generation of implementation experts and mentors.
Funding Opportunity PAR-22-216 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of cancer research (pre-clinical or clinical).
Notice NOT-OD-22-184 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-178 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-179 from the NIH Guide for Grants and Contracts
Notice NOT-DA-23-011 from the NIH Guide for Grants and Contracts
Notice NOT-OD-22-183 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-TR-22-029 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support basket clinical trials of drugs targeting shared molecular etiologies in more than one rare disease. To facilitate clinical trial start up, and leverage existing datasets, preference will be given to applications focusing on diseases that are under study by the Rare Disease Clinical Research Network (RDCRN), and that involve collaborations with RDCRN clinical investigators.
Funding Opportunity RFA-DK-22-009 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).